These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18413256)

  • 1. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
    Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
    Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
    Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
    Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheb activation of mTOR and S6K1 signaling.
    Hanrahan J; Blenis J
    Methods Enzymol; 2006; 407():542-55. PubMed ID: 16757352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
    Fingar DC; Blenis J
    Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheb promotes cell growth as a component of the insulin/TOR signalling network.
    Saucedo LJ; Gao X; Chiarelli DA; Li L; Pan D; Edgar BA
    Nat Cell Biol; 2003 Jun; 5(6):566-71. PubMed ID: 12766776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin.
    Saito K; Araki Y; Kontani K; Nishina H; Katada T
    J Biochem; 2005 Mar; 137(3):423-30. PubMed ID: 15809346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
    Lim KH; Counter CM
    Cancer Cell; 2005 Nov; 8(5):381-92. PubMed ID: 16286246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
    Vogt PK; Bader AG; Kang S
    Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
    Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
    Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila.
    Stocker H; Radimerski T; Schindelholz B; Wittwer F; Belawat P; Daram P; Breuer S; Thomas G; Hafen E
    Nat Cell Biol; 2003 Jun; 5(6):559-65. PubMed ID: 12766775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress.
    Patel PH; Tamanoi F
    J Cell Sci; 2006 Oct; 119(Pt 20):4285-92. PubMed ID: 17038544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation.
    Wells V; Downward J; Mallucci L
    Oncogene; 2007 Dec; 26(55):7709-14. PubMed ID: 17603562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-specific mutations in phosphatidylinositol 3-kinase.
    Vogt PK; Kang S; Elsliger MA; Gymnopoulos M
    Trends Biochem Sci; 2007 Jul; 32(7):342-9. PubMed ID: 17561399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively active Rheb induces oncogenic transformation.
    Jiang H; Vogt PK
    Oncogene; 2008 Sep; 27(43):5729-40. PubMed ID: 18521078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?
    Geering B; Cutillas PR; Vanhaesebroeck B
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):199-203. PubMed ID: 17371237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3 kinases in cancer: from oncogene artifact to leading cancer target.
    Zhao JJ; Roberts TM
    Sci STKE; 2006 Dec; 2006(365):pe52. PubMed ID: 17164467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the small GTPase Rheb by amino acids.
    Roccio M; Bos JL; Zwartkruis FJ
    Oncogene; 2006 Feb; 25(5):657-64. PubMed ID: 16170341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.